Novo Nordisk A/S $NVO Holdings Lowered by Calamos Wealth Management LLC

Calamos Wealth Management LLC trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 69.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 7,067 shares of the company’s stock after selling 15,697 shares during the quarter. Calamos Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $488,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Kingstone Capital Partners Texas LLC lifted its stake in Novo Nordisk A/S by 301,443.6% in the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock worth $690,560,000 after acquiring an additional 10,001,898 shares in the last quarter. Nuveen LLC purchased a new stake in Novo Nordisk A/S in the 1st quarter worth about $370,272,000. Amundi lifted its stake in Novo Nordisk A/S by 49.1% in the 1st quarter. Amundi now owns 4,938,507 shares of the company’s stock worth $331,576,000 after acquiring an additional 1,627,051 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Novo Nordisk A/S by 15,919.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock worth $72,523,000 after acquiring an additional 1,038,137 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Novo Nordisk A/S by 118.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,594,544 shares of the company’s stock worth $110,725,000 after acquiring an additional 864,579 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 3.0%

NVO opened at $54.41 on Monday. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $118.26. The business has a 50-day moving average of $56.24 and a 200-day moving average of $62.69. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The company has a market capitalization of $242.93 billion, a PE ratio of 14.95, a price-to-earnings-growth ratio of 2.50 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 22.53%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. Weiss Ratings reissued a “hold (c)” rating on shares of Novo Nordisk A/S in a research note on Tuesday, October 14th. Hsbc Global Res raised Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 1st. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Finally, BNP Paribas Exane raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price target for the company in a research note on Wednesday, August 13th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $76.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.